	US 11,850,215 B2
	Recombinant adenoviruses and stem cells comprising same
Chae Ok Yun, Seoul (KR); and Yan Li, Seoul (KR)
Assigned to GENEMEDICINE CO., LTD., Seongdong-gu seoul (KR)
Appl. No. 16/772,033
Filed by GENEMEDICINE CO., LTD., Seoul (KR)
PCT Filed Dec. 12, 2018, PCT No. PCT/KR2018/015800 § 371(c)(1), (2) Date Jun. 11, 2020, PCT Pub. No. WO2019/117632, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 10-2017-0171539 (KR), filed on Dec. 13, 2017.
Prior Publication US 2021/0069253 A1, Mar. 11, 2021
Int. Cl. A61K 35/28 (2015.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12N 5/0775 (2010.01)

CPC A61K 35/28 (2013.01) [A61P 35/00 (2018.01); C12N 5/0663 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10345 (2013.01); C12N 2830/008 (2013.01)]

8 Claims

1. A mesenchymal stem cell (MSC) for treating cancer comprising a recombinant adenovirus comprising a target gene and the nucleic acid sequence set forth in SEQ ID NO: 1,

wherein the MSC is infected for 50 hours or less with the recombinant adenovirus at a concentration of greater than 0.01 MOI to less than 100 MOI.